Please login to the form below

Not currently logged in
Email:
Password:

Amryt Pharma appoints new regulatory affairs head

Derval O’Carroll joins the rare disease-focused biopharma from Retrophin

Rare and orphan disease-focused biopharmaceutical group Amryt Pharma has appointed a new head of regulatory affairs in the form of Derval O’Carroll.

O’Carroll has over 25 years’ experience in the pharmaceutical industry and regulatory affairs business. Prior to joining Amryt, she served as senior director of regulatory affairs for rare disease group Retrophin.

Her previous roles have seen her provide regulatory, strategic and operational input to product teams and managing development-stage and commercial products.

Prior to her time at Retrophin, O’Carroll spent eleven years as a managing consultant at Real Regulatory, a consultancy specialising in European regulatory affairs, quality management systems and supply chain operations compliance.

Her new role will see her take responsibility for engagement with regulatory agencies and she will examine opportunities to pursue new orphan indications for Amryt’s Epidermolysis bullosa candidate.

Dr Joe Wiley, chief executive officer or Amryt Pharma, said: “We are delighted to further strengthen our senior management team with the appointment of Derval as head of regulatory affairs.

“Her expertise will be particularly valuable as we plan for completion of our ongoing AP101 phase III trial in EB.”

1st February 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....